Drug Profile
Pegfilgrastim biosimilar - Virchow Group
Alternative Names: PEG NeutrogenLatest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator Virchow Group
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 29 Nov 2022 No development reported - Phase-III for Neutropenia in India (SC) (Virchow Group pipeline, November 2022)
- 16 Jul 2020 Virchow Biotech completes a phase III trial in Neutropenia in India (SC) (CTRI2018-04-013221)
- 28 Dec 2018 No recent reports of development identified for phase-I development in Neutropenia(In volunteers) in India (SC)